THE TRIVIALIZATION OF THE USE OF MOUNJARO AND OZEMPIC AS RAPID WEIGHT LOSS MEDICATIONS
Keywords:
GLP-1 Receptor Agonists, Medication Trivialization, Obesity, Indiscriminate UseAbstract
Obesity constitutes a global public health challenge, and glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as Mounjaro and Ozempic, emerge as effective therapeutic alternatives. This study critically analyzes the trivialization process of using these medications as rapid weight loss strategies, identifying contributing factors and implications for public health. The research characterizes itself as exploratory with a qualitative nature, grounded in systematic bibliographic review of national and international scientific literature, with searches in recognized databases from 2020 to 2025. Results demonstrate that, although GLP-1 RA show proven efficacy in weight reduction in specific populations, their social appropriation for aesthetic purposes, disconnected from formal therapeutic indications, configures a complex phenomenon that articulates pharmacological, ethical, social, and regulatory dimensions. Risks associated with inappropriate use include gastrointestinal, metabolic, perioperative adverse effects, and potential impacts on male fertility. The study concludes that the trivialization of these medications reflects cultural structures that value thinness as synonymous with success, amplified by media campaigns and promises of quick solutions, compromising healthcare integrity and equity in treatment access.
